Brief: CSPC Pharmaceutical Initiates Phase IB Clinical Trial Of JMT206 Injection In China
29/09/2026 11:21
BRIEF-CSPC Pharmaceutical Initiates Phase IB Clinical Trial Of JMT206 Injection In China Sept 29 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
PHASE IB CLINICAL TRIAL OF JMT206 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS INITIATED AT FIRST STUDY CENTRE IN CHINA
PHASE IB TRIAL TO EVALUATE JMT206 INJECTION AS MONOTHERAPY OR WITH SEMAGLUTIDE IN OBESITY
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines